Provided by Tiger Trade Technology Pte. Ltd.

Rhythm Pharmaceuticals Inc.

110.00
+1.080.99%
Post-market: 110.000.00000.00%19:30 EDT
Volume:523.14K
Turnover:57.65M
Market Cap:7.57B
PE:-35.29
High:112.59
Open:109.38
Low:106.58
Close:108.92
52wk High:122.20
52wk Low:74.50
Shares:68.85M
Float Shares:65.39M
Volume Ratio:1.08
T/O Rate:0.80%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.1172
EPS(LYR):-3.1100
ROE:-117.04%
ROA:-30.96%
PB:73.54
PE(LYR):-35.37

Loading ...

Rhythm Pharmaceuticals price target lowered to $152 from $176 at Citizens

TIPRANKS
·
Mar 17

Rhythm Pharmaceuticals Inc : RBC Cuts Target Price to $130 From $140

THOMSON REUTERS
·
Mar 17

Stocks to Watch: Lensar, Rhythm Pharmaceuticals, TruBridge, Kaltura

Dow Jones
·
Mar 17

BRIEF-Rhythm Pharmaceuticals Announces Topline Results From Phase 3 Emanate Trial

Reuters
·
Mar 17

Rhythm Pharma Exec Says the 2022‑Launched Trial Was Partly Affected by the Rise of Glp‑1 Drugs, Which May Have Contributed to High Patient Dropout Rates

THOMSON REUTERS
·
Mar 17

Rhythm Pharma Exec Says Most Placebo Patients Stopped Treatment by Choice, While Most Setmelanotide Patients Discontinued Because of Side Effects

THOMSON REUTERS
·
Mar 17

Rhythm Pharma Exec Says Emanate Trail Saw an Avg 40% to 60% Patient Dropout Rate Across All Groups - Conf Call

THOMSON REUTERS
·
Mar 17

Rhythm reports EMANATE trial substudies did not meet primary endpoints

TIPRANKS
·
Mar 17

Rhythm Pharma's obesity drug fails to meet main goal in late-stage trial

Reuters
·
Mar 17

Rhythm Pharmaceuticals Shares Fall About 13% to $78.58 After the Bell Following Announcement That Emanate Phase 3 Trial Didn't Meet Primary Endpoints

THOMSON REUTERS
·
Mar 17

Rhythm Pharmaceuticals reports Phase 3 EMANATE trial misses primary endpoints for setmelanotide across four genetic substudies

Reuters
·
Mar 17

Rhythm Pharmaceuticals Inc: Plans to Continue Analysis of Emanate Dataset & Evaluate Potential Clinical Development Paths Forward

THOMSON REUTERS
·
Mar 17

Rhythm Pharmaceuticals Inc - No New Safety Signals Observed With Setmelanotide in Emanate Trial

THOMSON REUTERS
·
Mar 17

Rhythm Pharmaceuticals price target raised to $143 from $136 at Wells Fargo

TIPRANKS
·
Mar 12

A Look At Rhythm Pharmaceuticals (RYTM) Valuation After New Trial Data Earnings And Financing Updates

Simply Wall St.
·
Mar 10

Rhythm Pharmaceuticals Corporate Controller and CAO Christopher Paul German Disposes of Common Shares

Reuters
·
Mar 07

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Altimmune (ALT), Rhythm Pharmaceuticals (RYTM) and Cormedix (CRMD)

TIPRANKS
·
Mar 06

Rhythm Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Mar 02

Rhythm Says New Late-Stage Data for Obesity Drug Shows Strong Weight Loss, Hunger Reduction

MT Newswires Live
·
Mar 02

Rhythm Pharmaceuticals price target lowered to $140 from $141 at Canaccord

TIPRANKS
·
Mar 02